# DESCRIPTION

## FIELD OF INVENTION

- introduce IL-1 receptor antagonist protein

## BACKGROUND OF INVENTION

- describe IL-1 and its effects
- discuss therapeutic approaches for targeting IL-1
- summarize prior art on IL-1R antagonist protein
- describe limitations of anakinra
- introduce short peptides with IL-1R antagonist activity

## SUMMARY OF INVENTION

- introduce truncated forms of IL1RA
- describe properties and uses of peptides

## DEFINITIONS AND ABBREVIATIONS

- define IL1RA and IL1R1
- define affinity
- define Ilantafin/Ilantide
- define individual
- define polypeptide and protein
- define isolated polypeptide
- define amino acid residue
- define equivalent amino acid residue
- classify equivalent amino acids
- define bioactive agent
- define drug and medicament
- define treating and treatment
- define pharmacologically effective amount

## DETAILED DESCRIPTION OF THE INVENTION

### Inflammation

- define inflammation

### Interleukins

- introduce interleukins
- describe function of interleukins
- motivate IL-1
- describe IL-1 alpha
- describe IL-1 beta
- describe IL-1 receptor antagonist protein
- describe IL-1 receptors

### Peptide Fragments of the Present Invention

- introduce truncated forms of IL1RA
- describe improved properties over full-length IL1RA protein
- explain increased solubility and stability
- discuss lower cost of synthesis
- describe ability to bind to IL-1R1 and interfere with IL-1 beta binding
- outline desirable downstream effects
- explain passage across blood-brain barrier
- describe blood-brain barrier structure and function
- discuss correlation between molecular weight and penetration
- define 'fragment or variant thereof'
- describe functional equivalents of sequences
- outline specific embodiments of peptides
- describe contiguous amino acid sequences
- define 'variant of a peptide'
- explain sequence identity and homology
- discuss conservative and non-conservative substitutions
- outline non-naturally occurring amino acid residues
- describe modifications to peptide sequences
- outline isolated and synthetic peptides

### Synthetic Preparation

- describe methods for synthetic production of peptides

### Compound of the Present Invention

- describe compound comprising or consisting of a peptide according to the invention

### Multimeric Compound

- define multimeric compound
- describe embodiments of multimeric compound

### Methods

- describe methods of using peptides or compounds

### Pharmaceutical Formulation

- introduce pharmaceutical formulation
- describe solid form preparations
- describe liquid form preparations
- describe parenteral administration
- describe topical delivery
- describe transdermal administration
- describe nasal, pulmonary, and bronchial administration
- describe pharmaceutically acceptable salts and carriers

### Dosage

- define dosage requirements
- describe factors affecting dosage
- provide daily parenteral dosage regimen
- specify dosage ranges
- describe frequency of administration
- introduce unit dosage form concept
- define effective amount and effective level
- describe inter-individual differences in pharmacokinetics
- describe inter-individual differences in drug distribution
- describe inter-individual differences in metabolism
- introduce administration section
- describe main routes of administration
- describe oral administration limitations
- describe parenteral administration benefits
- describe peptide solubility and formulation
- introduce co-administration section
- describe co-administration with bioactive agents
- describe co-administration with anti-inflammatory drugs
- describe co-administration with anti-rheumatoid drugs
- describe co-administration with anti-neurodegenerative drugs
- introduce Behçet's disease
- describe symptoms and treatment
- motivate neurodegenerative disorders
- describe neurodegenerative disorders
- describe Alzheimer's disease
- motivate treatment of Alzheimer's disease
- describe Parkinson's disease
- motivate treatment of Parkinson's disease
- describe Huntington's disease
- motivate treatment of Huntington's disease
- describe Multiple sclerosis
- motivate treatment of Multiple sclerosis
- provide sequences of Interleukin-1 receptor antagonist protein
- describe isoforms of Interleukin-1 receptor antagonist protein
- provide further Ilantafin-Sequences
- list Ilantafin-Sequences

## EXAMPLES

### Example 1

- locate Ilantafin sequence motif in crystal structure

### Example 2

- analyze binding affinity of Ilantafin peptide

### Example 3

- test Ilantafin peptide inhibition of macrophage activation

### Example 4

- measure Ilantafin peptide inhibition of TNF-α secretion

### Example 5

- induce neurite outgrowth in primary cerebellar neurons
- analyze Ilantafin peptide effect on neurite outgrowth

### Example 6

- test Ilantafin peptide effect on neuronal cell death

### Example 7

- evaluate Ilantafin peptide effect on CIA in rats

### Example 8

- detect Ilantafin peptides in plasma and cerebrospinal fluid

### Example 9

- describe kainic acid-induced cytotoxicity method
- plate hippocampal neurons
- treat neurons with Ilantafin or IL1RA
- add kainic acid
- fix and stain cells
- estimate cell viability

